<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Med Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Med. Genet</journal-id>
<journal-title-group>
<journal-title>Medizinische Genetik</journal-title>
</journal-title-group>
<issn pub-type="ppub">0936-5931</issn>
<issn pub-type="epub">1863-5490</issn>
<publisher>
<publisher-name>Springer Medizin</publisher-name>
<publisher-loc>Munich</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30459487</article-id>
<article-id pub-id-type="pmc">6223758</article-id>
<article-id pub-id-type="publisher-id">206</article-id>
<article-id pub-id-type="doi">10.1007/s11825-018-0206-2</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Schwerpunktthema: Intelligenzminderung</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Autosomal dominant intellectual disability</article-title>
<trans-title-group>
<trans-title xml:lang="de">Autosomal-dominante Intelligenzminderung/geistige Behinderung</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wieczorek</surname>
<given-names>Dagmar</given-names>
</name>
<address>
<email>dagmar.wieczorek@hhu.de</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2176 9917</institution-id><institution-id institution-id-type="GRID">grid.411327.2</institution-id><institution>Institut für Humangenetik, Universitätsklinikum Düsseldorf, </institution><institution>Heinrich-Heine-Universität, </institution></institution-wrap>Universitätsstr. 1, 40225 Düsseldorf, Germany </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>11</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>11</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2018</year>
</pub-date>
<volume>30</volume>
<issue>3</issue>
<fpage>318</fpage>
<lpage>322</lpage>
<permissions>
<copyright-statement>© The Author(s) 2018</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access.</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>Intellectual disability (ID) is a heterogeneous entity defined as a substantial impairment of cognitive and adaptive function with an onset in early childhood and an IQ measure of less than 70. During the last few years, the next generation technologies, namely whole exome (WES) and whole genome sequencing (WGS), have given rise to the identification of many new genes for autosomal dominant (ADID), autosomal recessive (ARID) and X‑linked forms of ID (XLID). The prevalence of ID is 1.5–2% for milder forms (IQ &lt; 70) and 0.3–0.5% for more severe forms of ID (IQ &lt; 50). Up to now, about 650 genes for ADID have been reported and it is expected that there are at least 350 genes still unidentified. Although the ADID genes can easily be classified according to the associated clinical findings, e. g. different kind of seizures, abnormal body measurements, an advanced selection of reasonable genes for analyses is challenging. Many different panels for ID genes have been developed for a first diagnostic step, but more meaningful is the use of trio exome sequencing in individuals with sporadic ID. Using trio WES the mutation detection rate for <italic>de novo</italic> mutations in ID varies from 20 to 60%.</p>
<p>Further research is needed for the identification of the remaining ID genes, a deeply understanding of the pathways and the development of therapies for the mostly rare causes of ID.</p>
</abstract>
<trans-abstract id="Abs2" xml:lang="de">
<title>Zusammenfassung</title>
<p>Die Intelligenzminderung, geistige Behinderung, ist eine heterogene Entität, die definiert ist als Beeinträchtigung der kognitiven und adaptiven Funktionen mit einem Beginn im frühen Kindesalter und einem IQ von weniger als 70. Während der letzten Jahre haben die neuen Hochdurchsatz-Sequenzierungsverfahren, die Exom-Sequenzierung und die Genom-Sequenzierung, zur Identifizierung von zahlreichen neuen Genen für die autosomal-dominante, autosomal-rezessive und X‑gebundene Intelligenzminderung geführt. Die Prävalenz für die Intelligenzminderung ist mit 1,5–2 % für milde Formen (IQ &lt; 70) und mit 0,3–0,5 % für schwerere Formen der Intelligenzminderung (IQ &lt; 50) anzugeben. Bis zum jetzigen Zeitpunkt wurden ca. 650 Gene für eine autosomal-dominante Intelligenzminderung publiziert und es wird geschätzt, dass es mindestens noch 350 weitere Gene gibt, die bisher noch nicht identifiziert wurden. Grundsätzlich kann man die Gene nach den assoziierten klinischen Zeichen, z. B. verschiedene Formen der Epilepsie oder auffällige Körpermaße, in Untergruppen einteilen. Trotzdem ist eine sinnvolle Vorauswahl von Genen für die Analyse bei Intelligenzminderung eine große Herausforderung. Es wurden zahlreiche verschiedene Panels für den ersten diagnostischen Schritt entwickelt, dennoch muss man sagen, dass die Trio-Exom-Sequenzierung bei sporadischer Intelligenzminderung die Methode der Wahl ist. Mit dieser Methode kann man eine <italic>de novo</italic> Mutationsdetektionsrate von 20 bis 60 % erreichen.</p>
<p>Weitere Forschungsprojekte sind notwendig und sinnvoll, um die noch nicht identifizierten Gene für die Intelligenzminderung zu finden, die zugrunde liegenden Signalwege zu verstehen und Therapien für die meistens doch sehr seltenen Ursachen der Intelligenzminderung/geistigen Behinderung entwickeln zu können.</p>
</trans-abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Intellectual disability</kwd>
<kwd>Autosomal dominant</kwd>
<kwd>
<italic>De novo</italic>
</kwd>
<kwd>Next generation sequencing</kwd>
<kwd>Mosaicism</kwd>
</kwd-group>
<kwd-group xml:lang="de">
<title>Schlüsselwörter</title>
<kwd>Intelligenzminderung, autosomal-dominant</kwd>
<kwd>Geistige Behinderung</kwd>
<kwd>
<italic>De novo</italic>
</kwd>
<kwd>Hochdurchsatz-Sequenzierung</kwd>
<kwd>Mosaik</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p>Intellectual disability (ID) is a substantial impairment of cognitive and adaptive function with an onset in early childhood. An objective measure is an intelligence quotient (IQ) &lt; 70. Depending on the IQ measure, ID can be subdivided into mild (IQ: 55–70), moderate (IQ: 40–55), severe (IQ: 25–40) and profound (IQ &lt; 25).</p>
<p>Intellectual disability often co-occurs with other mental conditions, e. g. depression, attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). ID can be subdivided into non-syndromic and syndromic forms, the latter with additional clinical signs such as organ malformations. In many cases, the cause remains unknown owing to clinical and genetic heterogeneity.</p>
<p>The term “mental retardation” was used for many years to diagnose individuals with a reduced IQ. This term was considered to be no longer politically correct as “retard” stigmatizes those individuals [<xref ref-type="bibr" rid="CR1">1</xref>]. Thus, the term ID is used in this review.</p>
<p>Non-genetic causes of intellectual disability include pre- and postnatal infections, perinatal asphyxia, maternal conditions such as diabetes or phenylketonuria, premature birth, environmental factors (e. g. iodine deficiency, malnutrition), metabolic causes and teratogens (e. g. intrauterine exposure to alcohol, drugs, environmental chemicals). However, most of the environmental factors depend on maternal lifestyle and healthcare.</p>
<p>This review mainly focuses on the genetic causes of autosomal dominant ID, which are responsible at least for the more severe forms of ID. Autosomal recessive and X‑chromosomal ID and chromosomal aberrations are not included in this review. For this topic please have a look at Rami Jamra’s article “Genetics of autosomal recessive intellectual disability”, Andreas Tzschach’s article “X-chromosomale Intelligenzminderung” and Hartmut Engels’ article “Strukturelle Chromosomenstörungen bei Intelligenzminderung” in this issue.</p>
<p>Intellectual disability is mostly sporadic in Western populations where consanguinity of the parents is rare. In these individuals <italic>de novo</italic> copy variations and <italic>de novo</italic> mutations in single genes detected by whole exome sequencing (WES) or whole genome sequencing (WGS) are causative. <italic>De novo</italic> mutations account for 42% of the architecture of severe ID and it is hypothesized that the mutations might be equally split between loss of function and altered function [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
<p>At the beginning of the next generation sequencing era, ID was distinguished in syndromic and non-syndromic ID. As many of the phenotypes caused by mutations in ID genes are extremely variable, non-syndromic ID can be found at the mild end and syndromic ID at the more severe end for mutations in the same gene, e. g. Coffin-Siris syndrome [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Therefore, subdividing ID in these two groups is not warranted anymore, although associated clinical findings can help to find the causative gene.</p>
<p><italic>De novo </italic>mutations occur predominantly in the sperm cell or egg and result in an embryo with a germline mutation, but post-zygotic point mutations in the index patient or low-level mosaicism in one parent have also been described [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
<p>As ID is one of the most common themes in genetic services, the following article provides an update on this topic.</p>
</sec>
<sec id="Sec2">
<title>Prevalence of autosomal dominant ID</title>
<p>The prevalence of ID depends on the portion of consanguineous and non-consanguineous marriages. In Western populations with a low rate of consanguineous marriages, the prevalence of ID with an IQ &lt; 70 is estimated to be 1.5–2%; for severe ID (IQ &lt; 50) it is 0.3–0.5% [<xref ref-type="bibr" rid="CR6">6</xref>]. A very recent review of 20 relevant articles gives a similar range of 0.05 to 1.55% for ID [<xref ref-type="bibr" rid="CR7">7</xref>]. Two Australian surveys reported that the ID prevalence is age dependent with a prevalence of 1/303 in an age range of 20 to 50 years of the affected individuals, but increased to 1/70 if the age range was 6–15 years [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
<p>Developmental disorders caused by <italic>de novo</italic> mutations are reported to have an average prevalence of 1/448 (both parents aged 20) to 1/213 births (both parents aged 45) [<xref ref-type="bibr" rid="CR2">2</xref>]. ID itself is not a rare disorder, but each subgroup – caused by mutations in different genes – is rare.</p>
</sec>
<sec id="Sec3">
<title>Number of genes known to cause autosomal dominant ID</title>
<p>It is hypothesized that mutations in more than 1000 different genes might cause ID, some authors propose that the correct number is up to 2000 [<xref ref-type="bibr" rid="CR1">1</xref>]. The estimates differ from paper to paper but more than 400 genes for autosomal dominant ID have been identified so far [<xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR10">10</xref>]. The SysID database (<ext-link ext-link-type="uri" xlink:href="http://sysid.cmbi.umcn.nl/">http://sysid.cmbi.umcn.nl/</ext-link>, [<xref ref-type="bibr" rid="CR9">9</xref>]) lists 654 disease genes causing 535 diseases (as of 1 July, 2018), including 310 candidate genes. Fitzgerald et al. hypothesized in 2015 that most of the genes for autosomal dominant ID might have been identified [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
<p>In contrast, autosomal recessive ID (ARID) seems to be more heterogeneous and it is estimated that more than 3000 genes are involved [<xref ref-type="bibr" rid="CR12">12</xref>]. It is interesting to note that 6% of individuals with ID born to first cousins or closer had a plausibly pathogenic <italic>de novo</italic> mutation [<xref ref-type="bibr" rid="CR2">2</xref>]. For X‑linked ID, only 141 genes have been published up to 2017 [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
</sec>
<sec id="Sec4">
<title>Frequently mutated genes in autosomal dominant ID</title>
<p>It is challenging to find reliable information on this topic. Most of the papers do not give estimates for the frequency of mutations within their identified genes.</p>
<p>According to the DDD study the most commonly mutated genes in their cohort are <italic>ARID1B</italic> (Coffin-Siris syndrome), <italic>SCN2A, ANKRD11</italic> (KBG syndrome), <italic>SATB2</italic> (Glass syndrome), <italic>SYNGAP1, DYRK1A, MED13L, STXBP1, CTNNB1, KCNQ2, KMT2A</italic> (Wiedemann-Steiner syndrome), <italic>FOXP1, PACS1</italic> (Schuurs-Hoeijmakers syndrome), <italic>SMARCA2</italic> (Nicolaides-Baraitser syndrome) and <italic>WDR45</italic> [<xref ref-type="bibr" rid="CR11">11</xref>], all autosomal dominant genes besides WDR45. Some of these commonly mutated genes are causative for well-known syndromes and can now be identified in milder and more unspecified ID phenotypes.</p>
<p>Although the DDD consortium wrote in 2015 that the identification of genes for autosomal dominant ID is nearly completed, this seems not to be true. If all the publications in the <italic>American Journal of Human Genetics and Nature Genetics</italic> from January to June 2018 are analysed, 13 new genes for autosomal dominant ID have been published, namely <italic>WASF1, TRAF7, TLK2, RORA, NAA15, PACS2, DPF2, CDC42, RHOBTB2, DHX30, FBXO11, BCL11B</italic> and <italic>BRD4</italic>. It may be calculated that about 30 new genes for autosomal dominant ID will be identified by the end of this year, which is 10% of the known ID genes, excluding those that are only candidate genes (Table <xref ref-type="table" rid="Tab1">1</xref>; [<xref ref-type="bibr" rid="CR9">9</xref>]).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Estimated frequencies for mutations in commonly mutated genes in intellectual disability (ID) cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Frequency (%)</th></tr></thead><tbody><tr><td>
<italic>ARID1B</italic>
</td><td>0.5–1 [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]</td></tr><tr><td>
<italic>SCN2A</italic>
</td><td>0.5–16 [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]</td></tr><tr><td>
<italic>ANKRD11</italic>
</td><td>0.5–1 [<xref ref-type="bibr" rid="CR11">11</xref>]</td></tr><tr><td>
<italic>SATB2</italic>
</td><td>0.3 [<xref ref-type="bibr" rid="CR11">11</xref>]</td></tr><tr><td>
<italic>SYNGAP1</italic>
</td><td>0.5–16 [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]</td></tr><tr><td>
<italic>DYRK1A</italic>
</td><td>0.44 [<xref ref-type="bibr" rid="CR17">17</xref>]</td></tr><tr><td>
<italic>MED13L</italic>
</td><td>0.5–1 [<xref ref-type="bibr" rid="CR11">11</xref>]</td></tr><tr><td>
<italic>STXBP1</italic>
</td><td>0.5–16 [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]</td></tr><tr><td>
<italic>CTNNB1</italic>
</td><td>1–2 [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr><td>
<italic>KCNQ2</italic>
</td><td>3 [<xref ref-type="bibr" rid="CR20">20</xref>]</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="Sec5">
<title>Diagnostic rates in autosomal dominant ID</title>
<p>These data vary from 20 to 60% according to several factors, e. g. detailed clinical characterization of patients, heterogeneity of the condition, the applied technology, including coverage and the bioinformatic workflow and analyses of clinical data. A very recent paper from the DDD study summarized that trio WES has a diagnostic yield of 50% for affected individuals [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
<p>The technology used differs in research and diagnostics and can comprise panel sequencing, WES, WGS and also the third generation long-read sequencing with the PacBio and Nanopore technologies and Bionano mapping technologies [<xref ref-type="bibr" rid="CR22">22</xref>], which have not been used for diagnostic purposes so far. Proof of principles for these new technologies have been published and could demonstrate that additional mutations were detected with these methods, although extended experience for human data is still lacking. However, it may be expected that the mutation detection rate for ID will increase further (Table <xref ref-type="table" rid="Tab2">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Mutation detection rate for ID in selected studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reference</th><th>Vissers Lelm et al., 2010 [<xref ref-type="bibr" rid="CR23">23</xref>]</th><th>De Ligt et al.,<break></break>2012 [<xref ref-type="bibr" rid="CR18">18</xref>]</th><th>Rauch et al.,<break></break>2012 [<xref ref-type="bibr" rid="CR15">15</xref>]</th><th>DDD study, 2015 [<xref ref-type="bibr" rid="CR11">11</xref>]</th><th>DDD study et al., 2017 [<xref ref-type="bibr" rid="CR2">2</xref>]</th><th>Wright et al.,<break></break>2018 [<xref ref-type="bibr" rid="CR21">21</xref>]</th></tr></thead><tbody><tr><td>Number of patients analysed (<italic>n</italic>)</td><td>10</td><td>100</td><td>51</td><td>1133</td><td>148</td><td>1133</td></tr><tr><td>Method applied</td><td>Trio WES</td><td>Trio WES</td><td>Trio WES</td><td>Trio WES</td><td>Trio WES</td><td>Trio WES</td></tr><tr><td>Detection rate (%)</td><td>60</td><td>16</td><td>45–55</td><td>27</td><td>31</td><td>40–43</td></tr></tbody></table><table-wrap-foot><p><italic>WES</italic> whole exome sequencing</p></table-wrap-foot></table-wrap></p>
<p>Some of the early papers applying trio WES for the identification of mutations in ID included individuals with severe ID and thus the mutation detection rate was high, although the bioinformatic pipeline was in the fledgling stages. The more recent papers had larger and more heterogeneous cohorts of patients, especially the DDD study, and the mutation detection rate also increased owing to the optimization of the pipelines. This could be demonstrated by re-analysing the previous DDD cohort [<xref ref-type="bibr" rid="CR21">21</xref>]. However, the mutation detection rate depends on inclusion criteria, the quality of clinical and sequencing data and on the bioinformatic pipelines.</p>
</sec>
<sec id="Sec6">
<title>Increase in the mutation detection rate after re‑analysing the data</title>
<p>A few papers have been published dealing with re-analyses of WES data. Costain et al. [<xref ref-type="bibr" rid="CR24">24</xref>] re-analysed WES data of 100 patients 2 years later. They identified seven more causative variants in 64 previously undiagnosed patients and increased the diagnostic yield to 41%. Wright et al. [<xref ref-type="bibr" rid="CR21">21</xref>] re-analysed the data of 1133 children after 4 years and were able to diagnose an additional 182/1133 patients. The diagnostic yield increased from 27 to 40%. Alfares et al. [<xref ref-type="bibr" rid="CR25">25</xref>] reported in a study of 108 patients that WGS achieved an only 7% higher detection rate than WES. They described that in 4 patients, the variants were missed for different reasons in the first-run analyses of WES data.</p>
<p>One can conclude that the re-analysis of WES data is recommended before performing WGS.</p>
</sec>
<sec id="Sec7">
<title>Disease-causing mutations in more than one gene</title>
<p>It is well-known that in some individuals, the ID is caused by mutations in more than one gene. Fitzgerald et al. reported 17/148 (11%) individuals showing a composite phenotype due to disease-causing mutations in two genes [<xref ref-type="bibr" rid="CR2">2</xref>]. In a retrospective analysis of 7374 consecutive patients, not only ID patients, a molecular diagnosis was established after whole exome sequencing in 2076 patients and 4.9% of them had diagnoses that involved two or more disease loci [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
</sec>
<sec id="Sec8">
<title>Relevance of gender in autosomal dominant ID</title>
<p>Male patients with ID have a statistically significantly lower risk of carrying a pathogenic <italic>de novo</italic> mutation compared with female patients [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], which was also reported for autism [<xref ref-type="bibr" rid="CR27">27</xref>]. This can be explained by the fraction of mutations in X‑linked genes explaining the ID in these male individuals. For X‑linked ID in male patients, please refer to the article by Andreas Tzschach “X-chromosomale Intelligenzminderung” in this issue and for X‑linked ID in female patients the article by Christiane Zweier “X-gebundene Entwicklungsstörungen im weiblichen Geschlecht”.</p>
</sec>
<sec id="Sec9">
<title>Relevance of mosaicism in autosomal dominant ID</title>
<p>As Sanger sequencing does not provide reliable information for distinguishing between somatic and germline mutations, little is known about the proportion of <italic>de novo</italic> mutations that occurred during gametogenesis and the postzygotic mutations. Acuna-Hidalgo et al. analysed 107 <italic>de novo</italic> mutations in 50 parent-child trios concerning this question. They observed with WGS that 7/107 (6.5%) mutations were mosaic mutations in the blood, which were previously suspected to be germline mutations. Krupp et al. identified mosaic <italic>de novo</italic> mutations in 4.2% of individuals with autism spectrum disorder [<xref ref-type="bibr" rid="CR28">28</xref>]. This is of great importance for individuals as low-level mosaicism (1% in affected tissues) can be clinically significant, e. g. Sturge-Weber syndrome.</p>
<p>In addition, 4/4081 variants, which were classified to be <italic>de novo</italic>, were also present in the blood of one parent. Thus, parental mosaicism was the cause of these variants [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
<p>These findings have an impact on the genetic counselling of these families. If the mutation occurs post-zygotically in the child, the recurrence risk for further children of the parents is lower than expected for germline mutations. In contrast, if one parent shows low-level mosaicism, the recurrence risk for further children is higher than in <italic>de novo</italic> germline mutations.</p>
<p>Acuna-Hildalgo et al. concluded that there is a need for higher coverage in WES/WGS to detect mosaicism correctly [<xref ref-type="bibr" rid="CR5">5</xref>]. One should also keep in mind that in most of the studies only DNA from blood was analysed. More studies on other tissue samples, e. g. fibroblasts, saliva, urine, will give further insights into the relevance of mosaicism in ID. Especially for ID, the tissue of choice – brain tissue – cannot be analysed to find low-grade mosaicism that is causative for ID.</p>
</sec>
<sec id="Sec10">
<title>Relevance of parental age in autosomal dominant ID</title>
<p>It is well-known that advanced maternal age leads to an increase in chromosomal aberrations and an advanced paternal age to an increase in <italic>de novo</italic> point mutations. Only some of the papers on ID evaluated parental age of individuals with ID. Paternal age was only weakly associated with a risk of the child having a <italic>de novo</italic> mutation, but focusing on the minority of <italic>de novo</italic> mutations that were truncating and missense variants in known ID genes limited this effect. However, analysis of all high-confidence exonic and intronic autosomal <italic>de novo</italic> mutations (<italic>n</italic> = 8409) revealed a strong effect of paternal age [<xref ref-type="bibr" rid="CR2">2</xref>] and a milder effect of maternal age [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. There seems to be a paternal effect of 0.03606 <italic>de novo</italic> mutations per year and a maternal effect of 0.0172 <italic>de novo</italic> mutations per year [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
</sec>
<sec id="Sec11">
<title>Diagnostic approaches</title>
<p>Trio WES is the most efficient and convenient diagnostic tool for sporadic individuals with ID in general and for identifying autosomal dominant/<italic>de novo</italic> mutations specifically. In the near future, the bioinformatic pipelines will be optimized for WGS and it can be hypothesised that this technique might then become the method of choice. It is only a matter of time before we use long-read sequencing and long-read mapping to resolve those individuals without mutations in WES and short-read WGS, as has been demonstrated for single individuals [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
</sec>
<sec id="Sec12">
<title>Outlook</title>
<p>As discussed above the mutation detection rate is limited to 20–60%, mostly within the coding region of the exome. In principle, mutations can be detected in the non-coding regions of the genome when applying WGS. In practice, we are not able to detect all disease-causing variants in intronic regions, like enhancers, repressors or insulator mutations in intergenic regions so far. Novel algorithms were developed and must be developed in the future to identify not only intronic variants, but also exonic variants affecting splicing or generating novel splice sites [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Epigenetic changes [<xref ref-type="bibr" rid="CR33">33</xref>], di-/polygenic inheritance and parental germline mutations should also be taken into consideration when trying to resolve ID in general.</p>
<p>In addition, it may be speculated that the 350 as yet unidentified genes for autosomal dominant ID might cause rare diseases and that identification might benefit from large national and international collaborations.</p>
</sec>
</body>
<back>
<notes notes-type="COI-statement">
<title>Compliance with ethical guidelines</title>
<sec id="FPar1">
<title>Conflict of interest</title>
<p>D. Wieczorek declares that she has no competing interests.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiurazzi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pirozzi</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Advances in understanding – genetic basis of intellectual disability. F1000Res</article-title>
<source/>F1000 Fac Rev
          <year>2016</year>
<pub-id pub-id-type="doi">10.12688/f1000research.7134.1</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Deciphering Developmental Disorders Study</collab>
</person-group>
<article-title>Prevalence and architecture of de novo mutations in developmental disorders</article-title>
<source/>Nature
          <year>2017</year>
<volume>542</volume>
<fpage>433</fpage>
<lpage>438</lpage>
<pub-id pub-id-type="doi">10.1038/nature21062</pub-id>
<pub-id pub-id-type="pmid">28135719</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wieczorek</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bögershausen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Beleggia</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A comprehensive molecular study on Coffin-Siris and Nicolaides-Baraitser syndromes identifies a broad molecular and clinical spectrum converging on altered chromatin remodeling</article-title>
<source/>Hum Mol Genet
          <year>2013</year>
<volume>22</volume>
<issue>25</issue>
<fpage>5121</fpage>
<lpage>5135</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt366</pub-id>
<pub-id pub-id-type="pmid">23906836</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoyer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ekici</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Endele</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Haploinsufficiency of ARID1B, a member of the SWI/SNF – a chromatin-remodeling complex, is a frequent cause of intellectual disability</article-title>
<source/>Am J Hum Genet
          <year>2012</year>
<volume>90</volume>
<issue>3</issue>
<fpage>565</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2012.02.007</pub-id>
<pub-id pub-id-type="pmid">22405089</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Acuna-Hidalgo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kwint</surname>
<given-names>MP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Post-zygotic point mutations are an underrecognized source of de novo genomic variation</article-title>
<source/>Am J Hum Genet
          <year>2015</year>
<volume>97</volume>
<fpage>67</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2015.05.008</pub-id>
<pub-id pub-id-type="pmid">26054435</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonard</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>The epidemiology of mental retardation: challenges and opportunities in the new millennium</article-title>
<source/>Ment Retard Dev Disabil Res Rev
          <year>2002</year>
<volume>8</volume>
<fpage>117</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1002/mrdd.10031</pub-id>
<pub-id pub-id-type="pmid">12216056</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKenzie</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Milton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systematic review of the prevalence and incidence of intellectual disabilities: current trends and issues</article-title>
<source/>Curr Dev Disord Rep
          <year>2016</year>
<volume>3</volume>
<fpage>104</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.1007/s40474-016-0085-7</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lelieveld</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Reijnders</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Pfundt</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Meta-analysis of 2104 trios provides support for 10 new genes for intellectual disability</article-title>
<source/>Nat Neurosci
          <year>2016</year>
<volume>19</volume>
<fpage>1194</fpage>
<lpage>1196</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4352</pub-id>
<pub-id pub-id-type="pmid">27479843</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kochinke</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zweier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nijhof</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systematic phenomics analysis deconvolutes genes mutated in intellectual disability into biologically coherent modules</article-title>
<source/>Am J Hum Genet
          <year>2016</year>
<volume>98</volume>
<fpage>149</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2015.11.024</pub-id>
<pub-id pub-id-type="pmid">26748517</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vissers</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Gilissen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Veltman</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic studies in intellectual disability and related disorders</article-title>
<source/>Nat Rev Genet
          <year>2016</year>
<volume>17</volume>
<fpage>9</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1038/nrg3999</pub-id>
<pub-id pub-id-type="pmid">26503795</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>DDDS</collab>
</person-group>
<article-title>Large-scale discovery of novel genetic causes of developmental disorders</article-title>
<source/>Nature
          <year>2015</year>
<volume>519</volume>
<fpage>223</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="doi">10.1038/nature14135</pub-id>
<pub-id pub-id-type="pmid">25533962</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ropers</surname>
<given-names>HH</given-names>
</name>
</person-group>
<article-title>Genetics of early onset cognitive impairment</article-title>
<source/>Annu Rev Genomics Hum Genet
          <year>2010</year>
<volume>11</volume>
<fpage>161</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-genom-082509-141640</pub-id>
<pub-id pub-id-type="pmid">20822471</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neri</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Lubs</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Stevenson</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>X-linked intellectual disability update 2017</article-title>
<source/>Am J Med Genet
          <year>2018</year>
<volume>176 A</volume>
<fpage>1375</fpage>
<lpage>1388</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.38710</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Murtha</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>State</surname>
<given-names>MW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations revealed by whole-exome sequencing are strongly associated with autism</article-title>
<source/>Nature
          <year>2012</year>
<volume>485</volume>
<fpage>237</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1038/nature10945</pub-id>
<pub-id pub-id-type="pmid">22495306</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rauch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wieczorek</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Graf</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study</article-title>
<source/>Lancet
          <year>2012</year>
<volume>380</volume>
<fpage>1674</fpage>
<lpage>1682</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(12)61480-9</pub-id>
<pub-id pub-id-type="pmid">23020937</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mignot</surname>
<given-names>C</given-names>
</name>
<name>
<surname>von Stülpnagel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nava</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic and neurodevelopmental spectrum of SYNGAP1-associated intellectual disability and epilepsy</article-title>
<source/>J Med Genet
          <year>2016</year>
<volume>53</volume>
<fpage>511</fpage>
<lpage>522</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2015-103451</pub-id>
<pub-id pub-id-type="pmid">26989088</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McRae</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Clayton</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>TW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence, phenotype and architecture of developmental disorders caused by de novo mutation</article-title>
<source/>BioRxiv
          <year>2016</year>
<pub-id pub-id-type="doi">10.1101/049056</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Ligt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>van Bon</surname>
<given-names>BWM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diagnostic exome sequencing in persons with severe intellectual disability</article-title>
<source/>N Engl J Med
          <year>2012</year>
<volume>367</volume>
<fpage>1921</fpage>
<lpage>1929</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1206524</pub-id>
<pub-id pub-id-type="pmid">23033978</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuechler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Albrecht</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in beta-catenin (CTNNB1) appear to be a frequent cause of intellectual disability: expanding the mutational and clinical spectrum</article-title>
<source/>Hum Genet
          <year>2015</year>
<volume>134</volume>
<issue>1</issue>
<fpage>97</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-014-1498-1</pub-id>
<pub-id pub-id-type="pmid">25326669</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kothur</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Holman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Farnsworth</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diagnostic yield of targeted massively parallel sequencing in children with epileptic encephalopathy</article-title>
<source/>Seizure
          <year>2018</year>
<volume>59</volume>
<fpage>132</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2018.05.005</pub-id>
<pub-id pub-id-type="pmid">29852413</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>McRae</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Clayton</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Making new genetic diagnoses with old data: iterative reanalysis and reporting form genome-wide data in 1133 families with developmental disorders</article-title>
<source/>Genet Med
          <year>2018</year>
<pub-id pub-id-type="doi">10.1038/gim.2017.246</pub-id>
<pub-id pub-id-type="pmid">30279471</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Dijk</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Jaszczyszyn</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Naquin</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The third revolution in sequencing technology</article-title>
<source/>Trends Genet
          <year>2018</year>
<pub-id pub-id-type="doi">10.1016/j.tig.2018.05.008</pub-id>
<pub-id pub-id-type="pmid">29941292</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vissers</surname>
<given-names>L</given-names>
</name>
<name>
<surname>de Ligt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gilissen</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A de novo paradigm for mental retardation</article-title>
<source/>Nat Genet
          <year>2010</year>
<volume>42</volume>
<fpage>1109</fpage>
<lpage>1113</lpage>
<pub-id pub-id-type="doi">10.1038/ng.712</pub-id>
<pub-id pub-id-type="pmid">21076407</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costain</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jobling</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Periodic reanalysis of whole-genome sequencing data enhances the diagnostic advantage over standard clinical genetic testing</article-title>
<source/>Eur J Hum Genet
          <year>2018</year>
<pub-id pub-id-type="doi">10.1038/s41431-018-0114-6</pub-id>
<pub-id pub-id-type="pmid">29453418</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alfares</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aloraini</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Al Subaie</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing</article-title>
<source/>Genet Med
          <year>2018</year>
<pub-id pub-id-type="doi">10.1038/gim.2018.41</pub-id>
<pub-id pub-id-type="pmid">29565419</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Posey</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Harel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Resolution of disease phenotypes resulting from multilocus genomic variation</article-title>
<source/>N Engl J Med
          <year>2017</year>
<volume>376</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1516767</pub-id>
<pub-id pub-id-type="pmid">27959697</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacquemont</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Hersch</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A higher mutational burden in females supports a “female protective model” in neurodevelopmental disorders</article-title>
<source/>Am J Hum Genet
          <year>2014</year>
<volume>94</volume>
<issue>3</issue>
<fpage>415</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2014.02.001</pub-id>
<pub-id pub-id-type="pmid">24581740</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krupp</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Barnard</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Duffourd</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exonic mosaic mutations contribute risk for autism spectrum disorder</article-title>
<source/>Am J Hum Genet
          <year>2017</year>
<volume>101</volume>
<fpage>369</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2017.07.016</pub-id>
<pub-id pub-id-type="pmid">28867142</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Solomon</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Bodian</surname>
<given-names>DL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>New observations on maternal age effect on germline de novo mutations</article-title>
<source/>Nat Commun
          <year>2016</year>
<volume>7</volume>
<fpage>10486</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms10486</pub-id>
<pub-id pub-id-type="pmid">26781218</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merker</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Wenger</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Sneddon</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Long-read genome sequencing identifies causal structural variation in a Mendelian disease</article-title>
<source/>Genet Med
          <year>2018</year>
<volume>20</volume>
<fpage>159</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2017.86</pub-id>
<pub-id pub-id-type="pmid">28640241</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soukarieh</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Gaildrat</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hamieh</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exonic splicing mutations are more prevalent than currently estimated and can be predicted by using in silico tools</article-title>
<source/>Plos Genet
          <year>2016</year>
<volume>12</volume>
<fpage>e1005756</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1005756</pub-id>
<pub-id pub-id-type="pmid">26761715</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systematic computational identification of variants that activate exonic and intronic cryptic splice sites</article-title>
<source/>Am J Hum Genet
          <year>2017</year>
<volume>100</volume>
<fpage>751</fpage>
<lpage>765</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2017.04.001</pub-id>
<pub-id pub-id-type="pmid">28475858</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbosa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of rare de novo epigenetic variations in congenital disorders</article-title>
<source/>Nat Commun
          <year>2018</year>
<pub-id pub-id-type="doi">10.1038/s41467-018-04540-x</pub-id>
<pub-id pub-id-type="pmid">30135514</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>